For synchronising and controlling API delivery, Extrusion-Spheronization (E-S) offers pharmaceutical drug developers a robust technique to develop and manufacture today’s most complex oral solid-dose therapeutics.

Manufacturing oral solid-dose API's into spheres via Extrusion-Spheronization is not new. What is new is that, in the right hands, with the right capabilities, this well-understood process stands ready to help lead the development and manufacturing of both today's and tomorrow’s complex solid dose therapeutics.

• How delivering therapeutic compounds and molecules in spheronized forms will help you meet your most difficult drug product manufacturing objectives.

• Understanding the motivations for using extrusion-spheronization to support patient-friendly oral solid-dose drug strategies.

• Knowledge of how extrusion-spheronization can improve quality, safety, therapeutic efficacy, and dose compliance in a variety of therapeutic areas.

• Applications of extrusion-spheronization technology for both modified release capsules and multi-unit pellet systems (MUPS).

• A step-by-step walkthrough of the E-S manufacturing process

About Bora Pharmaceuticals

Bora Pharmaceuticals is a premier international cGMP CDMO specializing in complex oral solid dosage (tablets and capsules), liquids (solutions, suspensions, and nasal sprays), and semi-solids (creams and gels) pharmaceutical Rx and OTC products for late-phase clinical through commercial manufacturing and packaging. Bora owns and operates three state-of-the-art CGMP manufacturing facilities (Taiwan and Canada) built to the highest international standards for manufacturing, packaging, R&D, and analytical testing. We can handle high potency compounds, solvents, flammables, and IR/SR/ER release profile products.